Dialysis system having video display with ambient light adjustment

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Baxter International Inc., , Baxter Healthcare S.A. patent solves the following problem:

In general, the present disclosure relates to medical fluid delivery systems that use a pumping cassette. In particular, the present disclosure provides systems, methods and machinery for the cassette-based dialysis medical fluid therapy, including, but not limited to the use of peristaltic pumps and diaphragm pumps.

Our analysis of this patent is as follows:

Baxter International Inc., , Baxter Healthcare S.A.’s patent US 8870812 B2 deals with Dialysis system having video display with ambient light adjustment.
A medical therapy machine includes: an enclosure; a medical therapy machine component located within the enclosure; A video monitor is supported by the places and displaying at least one of the information and indicia associated with medical therapy; an ambient light sensor position with respect to the enclosure to be able to feel a level of ambient light impinging on the court; and implementing a justice configured to control a level of backlight brightness for video monitor based on the ambient light sensor noticed.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Seattle Genetics, Inc. patent solves the following problem:

A great deal of interest surrounded the use of monoclonal antibodies (mAbs) for the chosen delivery of cytotoxic agents to tumor cells. MMAF (N-methylvaline-valine-dolaisoleuine dolaproine-phenylalanine) is an auristatin relatively non-toxic, but less potent activity when conjugated to comprehend mAbs. MMAF has sent a C-terminal phenylalanine residue that attenuates the cytotoxic activity compared to its neutral counterpart, MMAE; This difference is most likely due to impaired intracellular access. However, conjugating MMAF comprehend antibody, such as the AC10 or 1F6, by a protease cleavable linker resulted in conjugates of> 2000 times more potent antigen-positive cells as compared to the unconjugated drug. Active target with mAbs facilitated intracellular delivery of MMAF; MMAF once released from the conjugate inside the cells the drug, it may have been trapped because of reduced ability to cross cellular membranes, thus increasing the intracellular concentration and therefore the potency of the conjugate. Through the use of cytotoxic drugs with impaired passive intracellular uptake could potentially lead to mab-drug conjugates with reduced systemic toxicity. In fact, non-specific cleavage of the linker to release circulation in a relatively non-toxic drug.

Our analysis of this patent is as follows:

Seattle Genetics, Inc.’s patent US 8871720 B2 deals with Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus.
Auristatin peptide analogs MeVal-Val-Dil-Dap-phe (MMAF) with a carboxylic acid equivalent to the C-terminal phenylalanine prepared and included the ligands by various linkers, including maleimidocaproyl-val-Cit- PAB. The result ligand drug conjugates active in vitro and in vivo.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of forming a masking pattern for integrated circuits

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Micron Technology, Inc. patent solves the following problem:

This creation relates generally to integrated circuit fabrication and, particularly, to masking techniques.

Our analysis of this patent is as follows:

Micron Technology, Inc.’s patent US 8871646 B2 deals with Methods of forming a masking pattern for integrated circuits.
In some embodiments, the method for forming a masking pattern for an integrated circuit made. In one picture, mandrels defining a first pattern formed on a first layer masking over a target layer. The second masking layer deposited at least partially fill the space in the first pattern. Offering structure formed between the mandrels and the second masking layer. After the second set masking layer and forming the sacrificial structures, and the present structure, which identifies gaps between the mandrels and the second masking layer, thus defining a second pattern. The second sample includes at least parts of the mandrels and intervening mask showed alternating with mandrels. The second example can be transferred to the target layer. In some embodiments, the method allows the construction of a high density and a small pitch while also allowing the formation of parts of various shapes and sizes .

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for forming high density patterns

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Micron Technology, Inc. patent solves the following problem:

Embodiments of the invention relate to semiconductor processing, and especially of masking techniques.

Our analysis of this patent is as follows:

Micron Technology, Inc.’s patent US 8871648 B2 deals with Method for forming high density patterns.
In one or more embodiments, a method given for the construction of an integrated circuit with a pattern in remote areas with a density in remote parts of more than one Density start in remote areas of an integrated circuit with a number of two or more. methods may include forming a pattern of pillars with a density X, and establish a pattern of holes in between the pillars, the holes that have a density of at least X. The pillars may selectively removed to form a pattern of holes with a density of at least 2x. In some embodiments, plugs can be formed with a pattern of holes, such as epitaxial deposition substrate to provide a pattern of pillars with a density 2x. In some embodiments, the pattern of holes can be transferred to the substrate etching.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Alpha-4-beta-7 heterodimer specific antagonist antibody

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Amgen Inc. patent solves the following problem:

Integrins are heterodimeric Type I transmembrane proteins formed by two subunits (one alpha subunit and a beta subunit), and handle many different cell-cell and cell-extracellular matrix interactions. Functionally, integrins that are shown to be involved in different biological processes, including leukocyte migration and recirculation and the immune response. In mammals, there are 18 known alpha subunit and eight known beta subunit, which combine to form 24 different integrins. Ligand specificity determined in large part on the particular combination of alpha and beta subunit expressed, while affinity for the ligand is modulated by integrin conformational changes and divalent educational trust.

Our analysis of this patent is as follows:

Amgen Inc.’s patent US 8871490 B2 deals with Alpha-4-beta-7 heterodimer specific antagonist antibody.
Have expressed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acid encoding them, and methods of making and using them.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of identifying a pair of binding partners

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Agency For Science, Technology And Research patent solves the following problem:

In vitro selection of desired biological macromolecules from a pool of available biological macromolecules become a useful tool in case of research in molecular interactions, medical imaging and diagnosis, or the generation of protein-based biopharmaceuticals including artificial antibody. In vitro display technology for selection of peptide and protein dependent on a physical connection between the peptide or protein and a nucleic acid encoding the same. A large group of techniques established for this purpose, with the most commonly used phage / virus display, ribosome display, cell surface display, peptide plasmids, mRNA display, DNA display, cDNA display and in vitro compartmentalisation including micro beads display (for reviews see eg Rothe, A., et al, FASEB J. (2006) 20, 1599-1610 .. Sergeeva, A., et al , Advanced Drug Delivery reviews (2006) 58, 1622-1654).

Our analysis of this patent is as follows:

Agency For Science, Technology And Research’s patent US 8871686 B2 deals with Methods of identifying a pair of binding partners.
The invention relates to methods of identifying a binding partner of a target molecule in a number of analyte molecules, including a number of peptide and / or protein. The target molecules are physical with a target labeling nucleic acid molecule. Each member of the plurality of analyte molecules physically linked to an analyte labeling nucleic acid molecules, each analyte was called nucleic acid molecule comprising a chosen nucleotide. This specific nucleotide sequences may include a sequence encoding a peptide / protein combined. The target molecule contacted analyte molecules and a complex between the target molecule and an analyte molecule forms. The mixture is divided into chambers. The target labeling nucleic acid molecules and the analyte labeling nucleic acid molecules involved and the massive extent permitted disintegrate. The linked nucleic acid molecules obtained, and the order is determined.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Amyloid-beta polypeptide vaccine

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The H. Lundbeck A/S patent solves the following problem:

Amyloidosis is the extracellular deposition of insoluble fibrils proteins to tissue damage and disease (Pepys, 1996. Tan et al, 1995; Kelly, 1996). The fibrils form when normally soluble proteins and peptides self-associate in an abnormal manner (Kelly, 1997).

Our analysis of this patent is as follows:

H. Lundbeck A/S’s patent US 8871212 B2 deals with Amyloid-beta polypeptide vaccine.
Declared the new methods and compositions for preventing diseases characterized by the deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A). Immunization is best made by the administration of analogs of autologous APP or one, said analogs that can induce antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous modified by the introduction of one or a few foreign, immunodominant and promiscuous T-cell epitopes. The methods and means include methods for preparing analogs and pharmaceutical formulations, as well as nucleic acid fragments, vector, transformed cells, polypeptides and pharmaceutical formulations.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ibc Pharmaceuticals, Inc. patent solves the following problem:

To address the clinical concerns of immunogenicity and suboptimal pharmacokinetics, cancer therapy with the monoclonal antibody, which came from murine to chimeric, humanized and fully human constructs. Similar to these developments continue efforts to develop more effective forms of the antibody, which to date includes different antibody isotypes, single-chain antibody fragment in monomeric or multimeric binding moieties, in particular mutations in the Fc region of the effector function or circulating half- (. Chames et al, Br J Pharmacol 2009, 157: 220-233) in life, and bispecific antibody many designs of different valency, building, and people.

Our analysis of this patent is as follows:

Ibc Pharmaceuticals, Inc.’s patent US 8871216 B2 deals with Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases.
Said it is the composition and method of use that contain hexavalent DNL complexes. At best, the building contains anti-CD20 and / or anti-CD22 antibody or fragment thereof. More preferably, the anti-CD20 antibody veltuzumab and anti-CD22 antibody epratuzumab. Administration of the subject hexavalent DNL complexes formulation apoptosis and cell death in the target cells in diseases such as B-cell lymphomas or leukemias, autoimmune diseases or immune dysfunction disease. In more preferred embodiments, the DNL building to increase the level of phosphorylated P38 and PTEN, reduced levels of phosphorylated Lyn, Akt, ERK, IKK / IB, increase expression of RKIP and Bax and decreased expression of Mcl-1 , Bcl-XL, Bcl -2, and phospho-BAD to target cells. The subject DNL complexes show EC50 values ​​for inhibiting tumor cell growth in the low nanomolar or sub-nanomolar concentration range.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and compositions for the treatment of immune disorders

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The University Of North Carolina At Chapel Hill patent solves the following problem:

The functions of plexins and their ligands, semaphorins, who carefully studied in the central nervous system (CNS). They represent two large families of molecules that transduce signals important for the regulation of neuronal ad and attractions, cell shape, motility and cell-cell interactions (Kruger et al, 2005 .. Tran et al, 2007). In addition to their role in the CNS, the different functions of plexins and semaphorins also recognized in heart development (Toyofuku et al, 2004), vascularization and angiogenesis (Gu et al, 2003a .. Serini et al, 2003) , and tumorigenesis (Neufeld and Kessler, 2008. Sierra et al, 2008). More recent data strongly indicate a role for this molecule in the immune system (Kikutani and Kumanogoh, 2003. Suzuki et al, 2008). For example, plexin-A1 is expressed in dendritic cells (DCs) and regulate DC interaction with T cells to affect adaptive immunity (Takegahara et al, 2006 .. Wong et al, 2003). Plexin-C1 also found on DCs, although its role is less certain and it will only slightly affect T cell activation (Walzer et al., 2005). A further paper showed high expression of plexin-D1 double-positive (DP) thymocytes and a role for this protein to control intrathymic migration of these cells from the cortical to medullary region (Choi et al., 2008). Therefore, plexins involved in various functions of the immune system.

Our analysis of this patent is as follows:

The University Of North Carolina At Chapel Hill’s patent US 8871205 B2 deals with Methods and compositions for the treatment of immune disorders.
The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, resulting in reduced plexin-A4 activities subject, and thus treat immune-related disorder. Inhibitor plexin-A4 activity includes, for example, plexin-A4 antibody and plexin-A4 fusion protein. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin 3A (Sema3A) activity, resulting in reduced Sema3A activity subject, thereby treating immune-related disorder. Inhibitor Sema3A activities include, for example, Sema3A antibody and Sema3A fusion protein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method of predicting acute appendicitis

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Children’s Medical Center Corporation patent solves the following problem:

Appendicitis is a condition characterized by inflammation of the appendix. All cases require removal of the inflamed appendix, either by laparotomy or laparoscopy. Untreated, mortality is high, mainly because of peritonitis and shock.

Our analysis of this patent is as follows:

Children’s Medical Center Corporation’s patent US 8871453 B2 deals with Method of predicting acute appendicitis.
Embodiments of the invention provide methods and devices for predicting the probability of acute appendicitis without invasive exploratory medical procedures. Some protein biomarkers: leucine-rich-2-glycoprotein (LRG); S100-A8 (calgranulin); -1-Acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-2-glycoprotein (AZGP1); Apolipoprotein D (APOD); -1-antichymotrypsin (SERPINA3); increased urine of patients with appendicitis. The methods and devices containing them to the level of these biomarkers and comparisons with the reference found in healthy people.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.